First-in-class therapy approved for schizophrenia
European Pharmaceutical Review
SEPTEMBER 27, 2024
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for schizophrenia in adults. Bristol Myers Squibb highlighted that Xanomeline is a dual M 1 – and M 4 -preferring muscarinic receptor agonist.
Let's personalize your content